IN2012DN00977A - - Google Patents

Info

Publication number
IN2012DN00977A
IN2012DN00977A IN977DEN2012A IN2012DN00977A IN 2012DN00977 A IN2012DN00977 A IN 2012DN00977A IN 977DEN2012 A IN977DEN2012 A IN 977DEN2012A IN 2012DN00977 A IN2012DN00977 A IN 2012DN00977A
Authority
IN
India
Prior art keywords
diabetes
type
postprandial hyperglycemia
spot treatment
dosage
Prior art date
Application number
Other languages
English (en)
Inventor
Philipee Perovitch
Marc Maury
Jean-Pierre Dumonteix
Original Assignee
Perovitch Philippe
Marc Maury
Dumonteix Jean Pierre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perovitch Philippe, Marc Maury, Dumonteix Jean Pierre filed Critical Perovitch Philippe
Publication of IN2012DN00977A publication Critical patent/IN2012DN00977A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
IN977DEN2012 2009-07-10 2010-07-07 IN2012DN00977A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0954819A FR2947729B1 (fr) 2009-07-10 2009-07-10 Composition pharmaceutique pour le traitement du diabete de type ii par voie trans-muqueuse buccale
PCT/FR2010/051426 WO2011004117A1 (fr) 2009-07-10 2010-07-07 Procédé et compositions pharmaceutiques pour le traitement de l'hyper glycémie post-prandiale du diabète de type ii par voie trans-muqueuse buccale

Publications (1)

Publication Number Publication Date
IN2012DN00977A true IN2012DN00977A (fr) 2015-04-10

Family

ID=41571558

Family Applications (1)

Application Number Title Priority Date Filing Date
IN977DEN2012 IN2012DN00977A (fr) 2009-07-10 2010-07-07

Country Status (10)

Country Link
US (1) US9161910B2 (fr)
EP (1) EP2451436A1 (fr)
JP (1) JP2012532852A (fr)
CN (1) CN102481254A (fr)
BR (1) BR112012000596A2 (fr)
FR (1) FR2947729B1 (fr)
IN (1) IN2012DN00977A (fr)
MX (1) MX337606B (fr)
RU (1) RU2543635C2 (fr)
WO (1) WO2011004117A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940116B1 (fr) * 2008-12-22 2012-07-06 Philippe Perovitch Formulation pour l'administration d'hypolipemiant par voie trans-muqueuse buccale
FR3000896B1 (fr) * 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
FR3031668A1 (fr) 2015-01-20 2016-07-22 Philippe Perovitch Dispositif d'administration d'un principe actif par voie per-muqueuse buccale.
FR3053244A1 (fr) 2016-07-01 2018-01-05 Philippe Perovitch Dispositif d'administration d'au moins un principe actif par voie per-muqueuse buccale.
CN107669683B (zh) * 2017-09-30 2020-07-03 杭州华东医药集团新药研究院有限公司 含有西格列汀与二甲双胍的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2071779C1 (ru) * 1993-05-12 1997-01-20 Хабаровский химико-фармацевтический завод Способ получения пантокрина для инъекций
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
SE528866C2 (sv) * 2005-07-01 2007-02-27 Volvo Lastvagnar Ab Anordning för att kontrollera höjden hos en last eller lastbärare bakom förarhytten hos en lastbil
WO2007027651A2 (fr) * 2005-08-30 2007-03-08 Abbott Laboratories Compositions pharmaceutiques utilisees comme inhibiteurs de la dipeptidyl peptidase iv (dpp-iv)
DE102006027790A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Typ-2-Diabetes Kombinations-Wafer
EP2068831A4 (fr) * 2006-07-28 2010-07-21 Novadel Pharma Inc Formulations anti-migraine en aérosol oral et procédés
FR2906140B1 (fr) 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs

Also Published As

Publication number Publication date
FR2947729A1 (fr) 2011-01-14
US20120190618A1 (en) 2012-07-26
JP2012532852A (ja) 2012-12-20
WO2011004117A1 (fr) 2011-01-13
MX2012000466A (es) 2012-04-19
MX337606B (es) 2016-03-10
RU2012104639A (ru) 2013-08-20
BR112012000596A2 (pt) 2016-02-10
EP2451436A1 (fr) 2012-05-16
FR2947729B1 (fr) 2012-01-20
US9161910B2 (en) 2015-10-20
CN102481254A (zh) 2012-05-30
RU2543635C2 (ru) 2015-03-10

Similar Documents

Publication Publication Date Title
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112015013809A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
BR112017008160A8 (pt) Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
NO20084919L (no) Oksadiazolidindionforbindelse
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2009001340A1 (es) Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto.
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
CL2007001886A1 (es) Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
IN2012DN00977A (fr)
MX2017004614A (es) Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas.
MX2015014007A (es) Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de accion prolongada.